Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Is ctDNA a good biomarker for advanced prostate cancer?

Vincenza Conteduca • 15 Feb 2022
GU Cancers 2022
Genitourinary Cancer Prostate Cancer

Vincenza Conteduca, MD, PhD, Scientific Institute of Romagna for the Study and Treatment of Tumors, Meldola, Italy, discusses the potential of ctDNA as a biomarker for advanced prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

Disclosures

V.C. has served as consultant/advisory board member for Janssen, Astellas, Merck, AstraZeneca, Bayer, BMS; has received speaker honoraria or travel support from Astellas, Janssen, Ipsen, Bayer and Sanofi.

More from Vincenza Conteduca

3:42
ctDNA level variation as an early predictor of survival in patients with mCRPC
Vincenza Conteduca • 15 Feb 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals